Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Techno DrugsDHA:TECHNODRUG -2.27%37 Current Ratio is 3.27 as of Mar. 2026, which is 47% above its 10-year median of 2.23. GuruFocus rates DHA:TECHNODRUG with a GF Score™ of 37/100. The stock has 10 warning signs investors should review. Among 998 Drug Manufacturers companies, Techno Drugs ranks better than 70.14% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Techno Drugs's current ratio for the quarter that ended in Mar. 2026 was 3.27.
Techno Drugs has a current ratio of 3.27. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Techno Drugs's Current Ratio or its related term are showing as below:
DHA:TECHNODRUG'
s Current Ratio Range Over the Past 10 Years
Min: 1.38 Med: 2.23 Max: 4.05
Current: 3.27
During the past 2 years, Techno Drugs's highest Current Ratio was 4.05. The lowest was 1.38. And the median was 2.23.
DHA:TECHNODRUG's Current Ratio is ranked better than 70.14% of 998
companies
in the Drug Manufacturers industry
Industry Median: 2
vs DHA:TECHNODRUG: 3.27
Techno Drugs (DHA:TECHNODRUG) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Techno Drugs Current Ratio Related Terms
Techno Drugs Current Ratio Historical Data
* Premium members only.
The historical data trend for Techno Drugs's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:TECHNODRUG vs ZTS, UTHR, VTRS: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Techno Drugs's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Techno Drugs Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Techno Drugs's Current Ratio distribution charts can be found below:
* The bar in red indicates where Techno Drugs's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Techno Drugs (DHA:TECHNODRUG) has a Current Ratio of 3.27 as of Mar. 2026. This is 47% above median its historical median of 2.23. Over the past decade, Techno Drugs' Current Ratio has ranged from 1.38 to 4.05. According to the industry distribution chart, Techno Drugs ranks #298 out of 998 companies in the Drug Manufacturers industry, placing it in the top 29.9%.
Is Techno Drugs' Current Ratio too high?
Techno Drugs' current Current Ratio of 3.27 is 47% above median its 10-year median of 2.23. Over the past 10 years, this metric has ranged from a low of 1.38 to a high of 4.05. The Drug Manufacturers industry median Current Ratio is 2.00. Techno Drugs' value of 3.27 is 63.5% above this industry median. Based on the distribution chart, Techno Drugs ranks #298 out of 998 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Techno Drugs has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Techno Drugs' Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Techno Drugs ranks #298 out of 998 companies for Current Ratio. This puts Techno Drugs in the upper half of its industry. The industry median Current Ratio is 2.00. Techno Drugs' value of 3.27 is 63.5% above this benchmark. Historically, Techno Drugs' own Current Ratio has ranged from 1.38 to 4.05 over the past decade. While the company's 10-year median is 2.23 vs. the industry median of 2.00, Techno Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Techno Drugs's current Current Ratio of 3.27 is 63.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Techno Drugs's current Current Ratio is 3.27, which is 47% above median its own 10-year median of 2.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Techno Drugs stock overvalued right now?
Techno Drugs (DHA:TECHNODRUG) has a current Current Ratio of 3.27. The current Current Ratio is 3.27, which is 47% above median its 10-year median of 2.23 and 63.5% above the Drug Manufacturers industry median of 2.00. Techno Drugs' overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Techno Drugs (DHA:TECHNODRUG), the current Current Ratio is 3.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score
Get the complete analysis for DHA:TECHNODRUG
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:TECHNODRUG has been successfully added to your 
